Meningococcal Vaccines Market: Infants, Adolescents, and Young Adults Primary Target Groups: Global Industry Analysis (2013 - 2017) & Opportunity Assessment (2018 - 2028)

  • Published: 2018-05-29
  • Report Code: REP-GB-1252

An Incisive, In-depth Analysis on the Meningococcal Vaccines Market

This study offers a comprehensive, 360 degree analysis on the Meningococcal Vaccines market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Meningococcal Vaccines market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Key market players are broadening their product range in developed markets like the U.S to demonstrate the impact of meningococcal vaccines in infants and meningococcal carriage in adolescents

The outbreak of meningococcal meningitis is a severe public health concern and while effective and affordable treatment options are available in the global market, the disease has been found to induce a high rate of mortality and create long-term neurological defects in infants and young children. 50% of bacterial meningitis cases are found in children below five years of age. The next age group susceptible to the disease is the 15 – 19 years category. Considering the predominant adverse impact of meningococcal meningitis on the young population, top companies like GlaxoSmithKline are working on expanding their product line – including the addition of new formulations – to cater to this demographic.

Increasing adoption rate among the younger population to be witnessed in the coming years

Growing incidence of meningococcal meningitis among young children and adolescents has prompted the inclusion of meningococcal vaccines in national immunisation programmes by the governments of various countries. Demand for meningococcal vaccines for infants surpasses other age groups. Very recently, a study evaluating the safety and efficacy of a new meningococcal vaccine in adolescents and children indicated a satisfactory short-term safety profile with enhanced levels of immunogenicity. It was also observed that individuals who were administered this vaccine developed immunity levels 9-13 times more than those individuals who were administered regular meningococcal vaccines.

With the outbreak of meningitis threatening the lives of countless young people all over the world, manufacturers are introducing newer molecule formulations and pipeline products in the global market. This is boosting the growth in demand for the various meningococcal vaccines currently being administered across hospitals, clinics, and other global medical facilities.

Meningococcal-Vaccines-Market.jpg

Lack of awareness of the harmful effects of meningitis on toddlers and young children is challenging growth in adoption of vaccination programmes

Studies indicate that parents of infants and young children are unaware of the disease pathogenesis of meningococcal meningitis and hence do not understand the importance of government initiated meningococcal vaccination programmes. This has eventually led to low adoption of meningococcal vaccines especially in toddlers and children. Consider these statistics:

  • Only 1 in 5 parents (about 21%) are aware of the most common manner in which children contract meningococcal disease

  • More than half (about 54%) of the parents are not aware that there are different strains of meningococcal bacteria that cause meningococcal meningitis

  • Over half (about 52%) of the parents do not know what specific vaccines are included in the immunisation schedule defined by the government in their country of residence

  • 7 out of 10 parents (about 69%) are not clear about the extent of damage caused by meningococcal meningitis

This awareness gap is the main factor responsible for low demand for meningococcal vaccines and this is expected to have a negative impact on revenue growth of the global meningococcal vaccines market. There is a need to initiate community awareness of the disease and the importance of administering prescribed vaccines so as to curb the proliferation of meningococcal meningitis at the global level. This activity can be initiated by government and healthcare organisations in collaboration with hospitals and clinics to educate parents and create the necessary awareness to encourage the adoption of meningococcal vaccines.

This Future Market Insights (FMI) report examines the global meningococcal vaccines market for the period 2013–2028. The primary objective of the report is to offer insights into market opportunity for meningitis vaccines and pipeline developments in the meningitis vaccines market. The global meningitis vaccines market has witnessed spontaneous changes in the immunisation landscape after the launch of new vaccines and initiation of public-private alliances to widen immunisation coverage. Meningococcal disease is prevalent in infants and young children. According to Centre for Disease Control and Prevention (CDC), over half of the bacterial meningitis cases occur in children less than five years of age. Approximately 10%-20% of these patients suffer from the severe consequences of meningitis including permanent damage and disability.

The market for meningococcal vaccines is primarily driven by enhanced access to vaccines in middle income countries, growing investment by manufacturers and governments to expand vaccine production, and mass immunisation campaigns. However, insufficient meningococcal immunisation coverage in low-income countries and restricted access due to stringent regulations are some of the factors limiting revenue growth of the global meningococcal vaccines market.

The global meningococcal vaccines market has been segmented on the basis of:

  • Product Type

  • Age Group

  • Distribution Channel

  • Region

The report analyses the global meningococcal vaccines market in terms of value (US$ Mn). The report begins with the market definition and explains the different types and causes of meningitis, highlighting bacterial meningitis. This section also explains the prevalence of different serogroups of N. meningitides across key regions. The journey of vaccine manufacturing explains the complex chain involving different nodes in the market and highlights how vaccines reach the market. The market viewpoint section includes FMI’s analysis on key trends, drivers, opportunities, trends and macro factors influencing the global market. Opportunity analysis provided in the section better equips clients with crystal clear decision making insights. Pipeline analysis provided in the subsequent section helps clients identify future competitors in the global market.

The report analyses the market based on regions and presents a comprehensive forecast in terms of value (US$ Mn) for the next 10 years. Regions covered in the report include:

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • Asia Pacific Excluding Japan (APEJ)

  • Japan

  • The Middle East and Africa (MEA)

Each of these section analyses the various regional markets by product type, age group, distribution channel and country. Regional introductory sections provide key insights on market dynamics for each region. These sections are mainly designed to provide the current scenario of meningococcal vaccines market and forecast for 2018-2028. A section on representative market participants presents a list of companies operating in each region, competitive landscape and intensity map of their presence in each region.

We have incorporated a robust methodology to substantiate our research

To arrive at the market size, we have used our in-house epidemiology data-based model to estimate the meningococcal vaccines market size. We have adopted the bottom-up approach to forecast the meningococcal vaccines market. Weighted average selling price has been considered to estimate the market size of various product types mentioned in the scope of the study. The country price is captured with the local currency. The local currency figures are then converted to USD to offer forecasts in a consistent currency standard. Furthermore, we have also considered the latest annual exchange rate to reflect the impact of the most recent economic conditions of each assessed country. The forecast presented in the report provides total revenue of currently approved meningococcal vaccine products over 2018–2028. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

In the next section of the report, a ‘Competitive Landscape’ is included to provide report audiences with a dashboard view of the key differentiators among the competitor firms. Market structure analysis provides tier wise breakdown of total market revenue. The section also provides company share analysis and brand share analysis for key market players. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the various market segments. Detailed profiles of players operating in global meningitis vaccines market are also provided in the report, which highlight company description, overview, product/segment overview, SWOT analysis, financial information, key developments related to the market and a strategic overview.

The next section of report analyses the market based on product types and presents the forecast in terms of value for the next 10 years. Meningococcal vaccine product types covered in the report include:

  • Polysaccharide Vaccines

  • Conjugate Vaccines

The next section of the report analyses the market based on age group and provides forecast in terms of value for the next 10 years. Based on age groups, the global market has been segmented in to

  • Infants

  • Children

  • Adolescents & Young Adults

  • Adults

The next section of the report analyses the market based on distribution channel for meningococcal vaccine products and provides forecast in terms of value for the next 10 years. Distribution channels covered in this report are:

  • Pharmacies

  • Community Clinics

  • Public Health Agencies

  • Others (hospital pharmacy, private market etc.)

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective. To understand key growth segments, Future Market Insights provides the ‘Attractiveness Index’ analysis to help clients identify real market opportunities.

Meningococcal Vaccines Market Reports - Table of Contents

Meningococcal Vaccines Market Reports - List of Tables

Table 1a: Factors Considered While Setting Vaccine Prices, By Company

Table 1b: Factors Considered While Setting Vaccine Prices, By Company

Table 02: Meningococcal Vaccines Market Pipeline Analysis (2017)

Table 03: North Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 04: North America Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Product Type

Table 05: North America Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Age Group

Table 06: North America Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 07: North America Meningococcal Vaccines Market Company Intensity Map

Table 08: Latin America Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 09: Latin America Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Product Type

Table 10: Latin America Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Age Group

Table 11: Latin America Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 12: Latin Meningococcal Vaccines Market Company Intensity Map

Table 13: Western Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 14: Western Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Product Type

Table 15: Western Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Age Group

Table 16: Western Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 17: Western Europe Meningococcal Vaccines Market Company Intensity Map

Table 18: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 19: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Product Type

Table 20: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Age Group

Table 21: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 22: Eastern Europe Meningococcal Vaccines Market Company Intensity Map

Table 23: APEJ Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 24: APEJ Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Product Type

Table 25: APEJ Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Age Group

Table 26: APEJ Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 27: APEJ Meningococcal Vaccines Market Company Intensity Map

Table 28: Japan Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Product Type

Table 29: Japan Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Age Group

Table 30: Japan Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 31: Japan Meningococcal Vaccines Market Company Intensity Map

Table 32: MEA Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Country

Table 33: MEA Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Product Type

Table 34: MEA Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Age Group

Table 35: MEA Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Table 36: MEA Meningococcal Vaccines Market Company Intensity Map

Table 37: Global Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Region

Table 38: Global Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Product Type

Table 39: Global Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Age Group

Table 40: Global Meningococcal Vaccines Market Size (US$ Mn) Analysis 2013-2017 and Forecast 2018-2028, By Distribution Channel

Meningococcal Vaccines Market Reports - List of Figures

Figure 01: Wheel of Fortune

Figure 02: Predominant Serogroups Associated with Invasive Meningococcal Disease Worldwide

Figure 03: A Complex Journey of Vaccines

Figure 04 : Global Healthcare Expenditure in US$ Tn (2013–2020)

Figure 05: Tiered-price Policies Among Vaccine Manufacturers

Figure 06: Biotechnology Mergers and Acquisition Transactions and Number of deals (2013-2017)

Figure 07: Meningococcal Vaccine Immunization Coverage (Mn people) in Africa (2011-2017)

Figure 08: Weekly number of suspected meningitis cases — Nigeria, December 2016–June 2017

Figure 09: Gavi Transition Process

Figure 10: Gavi’s Strategic Demand (2014-2016) and Forecast Meningococcal A Vaccine Requirements (2017-2030)

Figure 11: Global Coverage of Older Vaccines vs.  Newer Vaccines (2016)

Figure 12: Opportunity In Emerging Markets

Figure 13: Distribution of Industry Sponsored Clinical Programs for Meningococcal Vaccines, by Phase

Figure 14: Distribution of Industry Sponsored Clinical Programs for Meningococcal Vaccines, by Age Group

Figure 15: Geographical Distribution of Clinical Trials for Meningococcal Vaccines (2017)

Figure 16: North America Meningococcal Vaccines Market Value Analysis By Product Type (2017 & 2028) 

Figure 17: North America Meningococcal Vaccines Market Value Share (%), By End User (2017 & 2028) 

Figure 18: North Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017,

Figure 19: North Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 20: U.S. Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 21: U.S. Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 22: Canada Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 23: Canada Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 24: North America Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Polysaccharide Vaccines

Figure 25: North America Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Polysaccharide Vaccines

Figure 26: North America Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Conjugate Vaccines

Figure 27: North America Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Conjugate Vaccines

Figure 28: North America Meningococcal Vaccines Market Attractiveness Analysis, By Country

Figure 29: North America Meningococcal Vaccines Market Attractiveness Analysis, By Product Type

Figure 30: North America Meningococcal Vaccines Market Attractiveness Analysis, By Age Group

Figure 31: North America Meningococcal Vaccines Market Attractiveness Analysis, By Distribution Channel

Figure 32: North America Meningococcal Vaccines Market Company Share Analysis (2017)

Figure 33: Latin America Meningococcal Vaccines Market Value Analysis By Product Type (2017 & 2028) 

Figure 34: Latin America Meningococcal Vaccines Market Value Share (%), By End User (2017 & 2028) 

Figure 35: Latin America Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017,

Figure 36: Latin America Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 37: Brazil Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 38: Brazil Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 39: Mexico Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 40: Mexico Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 41: Rest of Latin America Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 42: Rest of Latin America Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 43: Latin America Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Polysaccharide Vaccines

Figure 44: Latin America Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Polysaccharide Vaccines

Figure 45: Latin America Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Conjugate Vaccines

Figure 46: Latin America Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Conjugate Vaccines

Figure 47: Latin America Meningococcal Vaccines Market Attractiveness Analysis, By Country

Figure 48: Latin America Meningococcal Vaccines Market Attractiveness Analysis, By Product Type

Figure 49: Latin America Meningococcal Vaccines Market Attractiveness Analysis, By Age Group

Figure 50: Latin America Meningococcal Vaccines Market Attractiveness Analysis, By Distribution Channel

Figure 51: Latin America Meningococcal Vaccines Market Company Share Analysis (2017)

Figure 52: Western Europe Meningococcal Vaccines Market Value Analysis By Product Type (2017 & 2028) 

Figure 53: Western Europe Meningococcal Vaccines Market Value Share (%), By End User (2017 & 2028) 

Figure 54: Western Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017,

Figure 55: Western Europe Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 56: Germany Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 57: Germany Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 58: France Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 59: France Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 60: U.K. Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 61: U.K. Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 62: Spain Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 63: Spain Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 64: Italy Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 65: Italy Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 66: Rest of Western Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 67: Rest of Western Europe Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 68: Western Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Polysaccharide Vaccines

Figure 69: Western Europe Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Polysaccharide Vaccines

Figure 70: Western Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Conjugate Vaccines

Figure 71: Western Europe Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Conjugate Vaccines

Figure 72: Western Europe Meningococcal Vaccines Market Attractiveness Analysis, By Country

Figure 73: Western Europe Meningococcal Vaccines Market Attractiveness Analysis, By Product Type

Figure 74: Western Europe Meningococcal Vaccines Market Attractiveness Analysis, By Age Group

Figure 75: Western Europe Meningococcal Vaccines Market Attractiveness Analysis, By Distribution Channel

Figure 76: Western Europe Meningococcal Vaccines Market Company Share Analysis (2017)

Figure 77: Eastern Europe Meningococcal Vaccines Market Value Analysis By Product Type (2017 & 2028) 

Figure 78: Eastern Europe Meningococcal Vaccines Market Value Share (%), By End User (2017 & 2028) 

Figure 79: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017,

Figure 80: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 81: Russia Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 82: Russia Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 83: Poland Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 84: Poland Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 85: Rest of Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 86: Rest of Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 87: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Polysaccharide Vaccines

Figure 88: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Polysaccharide Vaccines

Figure 89: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Conjugate Vaccines

Figure 90: Eastern Europe Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Conjugate Vaccines

Figure 91: Eastern Europe Meningococcal Vaccines Market Attractiveness Analysis, By Country

Figure 92: Eastern Europe Meningococcal Vaccines Market Attractiveness Analysis, By Product Type

Figure 93: Eastern Europe Meningococcal Vaccines Market Attractiveness Analysis, By Age Group

Figure 94: Eastern Europe Meningococcal Vaccines Market Attractiveness Analysis, By Distribution Channel

Figure 95: Eastern Europe Meningococcal Vaccines Market Company Share Analysis (2017)

Figure 96: APEJ Meningococcal Vaccines Market Value Analysis By Product Type (2017 & 2028) 

Figure 97: APEJ Meningococcal Vaccines Market Value Share (%), By End User (2017 & 2028) 

Figure 98: APEJ Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017,

Figure 99: APEJ Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 100: China Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 101: China Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 102: India Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 103: India Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 104: ASEAN Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 105: ASEAN Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 106: ANZ Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 107: ANZ Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 108: Rest of APEJ Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 109: Rest of APEJ Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 110: APEJ Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Polysaccharide Vaccines

Figure 111: APEJ Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Polysaccharide Vaccines

Figure 112: APEJ Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Conjugate Vaccines

Figure 113: APEJ Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Conjugate Vaccines

Figure 114: APEJ Meningococcal Vaccines Market Attractiveness Analysis, By Country

Figure 115: APEJ Meningococcal Vaccines Market Attractiveness Analysis, By Product Type

Figure 116: APEJ Meningococcal Vaccines Market Attractiveness Analysis, By Age Group

Figure 117: APEJ Meningococcal Vaccines Market Attractiveness Analysis, By Distribution Channel

Figure 118: APEJ Meningococcal Vaccines Market Company Share Analysis (2017)

Figure 119: Japan Meningococcal Vaccines Market Value Analysis By Product Type (2017 & 2028) 

Figure 120: Japan Meningococcal Vaccines Market Value Share (%), By End User (2017 & 2028) 

Figure 121: Japan Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Polysaccharide Vaccines

Figure 122: Japan Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Polysaccharide Vaccines

Figure 123: Japan Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Conjugate Vaccines

Figure 124: Japan Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Conjugate Vaccines

Figure 125: Japan Meningococcal Vaccines Market Attractiveness Analysis, By Product Type

Figure 126: Japan Meningococcal Vaccines Market Attractiveness Analysis, By Age Group

Figure 127: Japan Meningococcal Vaccines Market Attractiveness Analysis, By Distribution Channel

Figure 128: Japan Meningococcal Vaccines Market Company Share Analysis (2017)

Figure 129: MEA Meningococcal Vaccines Market Value Analysis By Product Type (2017 & 2028) 

Figure 130: MEA Meningococcal Vaccines Market Value Share (%), By End User (2017A) 

Figure 131: MEA Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017,

Figure 132: MEA Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 133: GCC Countries Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 134: GCC Countries Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 135: South Africa Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 136: South Africa Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 137: Rest of MEA Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Country

Figure 138: Rest of MEA Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 139: MEA Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Polysaccharide Vaccines

Figure 140: MEA Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Polysaccharide Vaccines

Figure 141: MEA Meningococcal Vaccines Market Size (US$ Mn) Analysis, 2013–2017, By Conjugate Vaccines

Figure 142: MEA Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028, By Conjugate Vaccines

Figure 143: MEA Meningococcal Vaccines Market Attractiveness Analysis, By Country

Figure 144: MEA Meningococcal Vaccines Market Attractiveness Analysis, By Product Type

Figure 145: MEA Meningococcal Vaccines Market Attractiveness Analysis, By Age Group

Figure 146: MEA Meningococcal Vaccines Market Attractiveness Analysis, By Distribution Channel

Figure 147: MEA Meningococcal Vaccines Market Company Share Analysis (2017)

Figure 148: Global Meningococcal Vaccines Market Company Share Analysis (2017)

Figure 149: Global Meningococcal Vaccines Market Attractiveness Analysis, By Region

Figure 150: Global Meningococcal Vaccines Market Attractiveness Analysis, By Product Type

Figure 151: Global Meningococcal Vaccines Market Attractiveness Analysis, By Age Group

Figure 152: Global Meningococcal Vaccines Market Attractiveness Analysis, By Distribution Channel

Figure 153: Global Single-Photon Emission Computed Tomography Historical Market Size and Y-o-Y, 2012 - 2016

Figure 154: Global Meningococcal Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), 2018–2028

Figure 155: Global Meningococcal Vaccines Market Absolute $ Opportunity, 2012–2027

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields.

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology